Premium
Daily subcutaneous amifostine administration during irradiation of pediatric head and neck cancers
Author(s) -
Anacak Yavuz,
Kamer Serra,
Haydaroglu Ayfer
Publication year - 2007
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.20740
Subject(s) - amifostine , medicine , radiation therapy , head and neck cancer , nausea , head and neck , surgery
Five pediatric patients with head and neck cancers were treated with radiotherapy. Subcutaneous injections of 200 mg flat dose amifostine were given 30 min prior to radiation fractions. A total of 129 amifostine injections were done. Grade 3 nausea occurred three times and emesis only once. Hypotension, hypocalcemia, or allergic reactions following injections were not recorded. No grade 3 or 4 mucosal or skin reactions occurred. After 16 months, all patients were alive and disease‐free. There were no grade 3 or 4 side effects of radiotherapy on follow‐up. Further studies with more patients are required to determine the role of amifostine in pediatric radiation oncology, but these data should contribute to the clinical spectrum of amifostine use in pediatric oncology. Pediatr Blood Cancer 2007;48:579–581. © 2006 Wiley‐Liss, Inc.